mutLBSgeneDB |
Gene summary for KLK2 |
![]() |
Basic gene Info. | Gene symbol | KLK2 |
Gene name | kallikrein-related peptidase 2 | |
Synonyms | KLK2A2|hGK-1|hK2 | |
Cytomap | UCSC genome browser: 19q13.41 | |
Type of gene | protein-coding | |
RefGenes | NM_001002231.2, NM_001256080.1,NM_005551.4,NR_045762.1,NR_045763.1, NM_001002232.2, | |
Description | glandular kallikrein 2glandular kallikrein-1kallikrein 2, prostatickallikrein-2tissue kallikrein-2 | |
Modification date | 20141207 | |
dbXrefs | MIM : 147960 | |
HGNC : HGNC | ||
Ensembl : ENSG00000167751 | ||
HPRD : 01006 | ||
Vega : OTTHUMG00000182963 | ||
Protein | UniProt: P20151 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_KLK2 | |
BioGPS: 3817 | ||
Pathway | NCI Pathway Interaction Database: KLK2 | |
KEGG: KLK2 | ||
REACTOME: KLK2 | ||
Pathway Commons: KLK2 | ||
Context | iHOP: KLK2 | |
ligand binding site mutation search in PubMed: KLK2 | ||
UCL Cancer Institute: KLK2 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID |
Top |
Ligand binding site mutations for KLK2 |
![]() We represented ligand binding site mutations only. (You can see big image via clicking.) ![]() |
![]() |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | A241 | Y243H | BLCA | 1 | A241 | P240L | BRCA | 1 | S213 | S213Y | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for KLK2 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | A241 | Y243H | -0.67483061 | A241 | P240L | -0.31248954 | S213 | S213Y | -0.16956772 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for KLK2 |
![]() |
![]() |
Top |
Top |
Phenotype information for KLK2 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
umls:C0033578 | Prostatic Neoplasms | 8 | AlteredExpression, Biomarker, GeneticVariation |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for KLK2 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
Top |
Conservation information for LBS of KLK2 |
![]() |
LBS | AA sequence | # species | Species |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |